Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

69.70
-2.8800-3.97%
Post-market: 69.700.00000.00%18:22 EDT
Volume:1.23M
Turnover:85.87M
Market Cap:13.51B
PE:-18.44
High:73.03
Open:72.33
Low:69.44
Close:72.58
52wk High:84.94
52wk Low:28.33
Shares:193.86M
Float Shares:151.20M
Volume Ratio:0.71
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7800
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-33.83%
PB:-6.48
PE(LYR):-18.41

Loading ...

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 18

BridgeBio Pharma Inc. to announce fourth quarter and full year 2025 financial results and business update

Reuters
·
Feb 17

BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 17

BridgeBio Pharma, Inc. : H.c. Wainwright Raises Target Price to $100 From $90

THOMSON REUTERS
·
Feb 17

BridgeBio price target raised to $100 from $90 at H.C. Wainwright

TIPRANKS
·
Feb 17

U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR

Reuters
·
Feb 17

Kyowa Kirin Announces Positive Phase 3 Results for Infigratinib in Achondroplasia

Reuters
·
Feb 16

U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections

Reuters
·
Feb 13

BridgeBio Pharma CEO Neil Kumar Reports Disposal of Common Shares

Reuters
·
Feb 13

BridgeBio Oncology Therapeutics to Present at Major Healthcare Investor Conferences

Reuters
·
Feb 13

BridgeBio price target raised to $100 from $85 at Jefferies

TIPRANKS
·
Feb 13

BUZZ-U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln National

Reuters
·
Feb 13

BridgeBio Pharma (BBIO) Receives a Buy from TD Cowen

TIPRANKS
·
Feb 13

BUZZ-U.S. STOCKS ON THE MOVE-Iron Mountain, BridgeBio, Old Dominion,

Reuters
·
Feb 12

BridgeBio Shares up 10.44% After Positive Late-Stage Trial Results for Oral Genetic Disorder Drug

THOMSON REUTERS
·
Feb 12

BridgeBio Pharma Reports Positive Phase 3 Results for Oral Infigratinib in Achondroplasia

Reuters
·
Feb 12

BridgeBio: Intends to Meet With Regulatory Authorities to Discuss Plans for Submission of Nda & Maa for Infigratinib in H2 2026

THOMSON REUTERS
·
Feb 12

BridgeBio: Propel 3 Successfully Met Primary Endpoint of Change From Baseline in Ahv at Week 52

THOMSON REUTERS
·
Feb 12

BridgeBio: Infigratinib Was Well-Tolerated, With No Discontinuations, No Serious Adverse Events Related to Study Drug

THOMSON REUTERS
·
Feb 12

BridgeBio: Announced Positive Topline Results From Propel 3, Global Phase 3 Pivotal Study of Oral Infigratinib in Children With Achondroplasia

THOMSON REUTERS
·
Feb 12